The E.V.P., General Counsel of Myriad Genetics is Exercising Options


Today, the E.V.P., General Counsel of Myriad Genetics, Richard M. Marsh, exercised options of Myriad Genetics (NASDAQ: MYGN) for $1.26M.

In addition to Richard M. Marsh, one other MYGN executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

MYGN’s market cap is $2.55B and the company has a P/E ratio of 18.72. Currently, Myriad Genetics has an average volume of 1.13M.

10 different firms, including Merrill Lynch and Citigroup, currently also have a Sell rating on the stock. Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $36.33, reflecting a 8.6% upside.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts